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Influenza A virus is well known for its capability for genetic changes either through antigen drift or antigen
shift. Antigen shift is derived from reassortment of gene segments between viruses, and may result in an
antigenically novel virus that is capable of causing a worldwide pandemic. As we trace backwards through
the history of influenza pandemics, a repeating pattern can be observed, namely, a limited wave in the first
year followed by global spread in the following year. In the 20th century alone, there were three overwhelming
pandemics, in 1918, 1957 and 1968, caused by H1N1 (Spanish flu), H2N2 (Asian flu) and H3N2 (Hong
Kong flu), respectively. In 1957 and 1968, excess mortality was noted in infants, the elderly and persons with
chronic diseases, similar to what occurred during interpandemic periods. In 1918, there was one distinct
peak of excess death in young adults aged between 20 and 40 years old; leukopenia and hemorrhage were
prominent features. Acute pulmonary edema and hemorrhagic pneumonia contributed to rapidly lethal
outcome in young adults. Autopsies disclosed multiple-organ involvement, including pericarditis, myocarditis,
hepatitis and splenomegaly. These findings are, in part, consistent with clinical manifestations of human
infection with avian influenza A H5N1 virus, in which reactive hemophagocytic syndrome was a characteristic
pathologic finding that accounted for pancytopenia, abnormal liver function and multiple organ failure. All
the elements of an impending pandemic are in place. Unless effective measures are implemented, we will
likely observe a pandemic in the coming seasons. Host immune response plays a crucial role in disease caused
by newly emerged influenza virus, such as the 1918 pandemic strain and the recent avian H5N1 strain.
Sustained activation of lymphocytes and macrophages after infection results in massive cytokine response,
thus leading to severe systemic inflammation. Further investigations into how the virus interacts with the
host’s immune system will be helpful in guiding future therapeutic strategies in facing influenza pandemics.
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The influenza A virus, being a member of the Or-
thomyxoviridae family, possesses a genome make-
up of eight single-stranded, negative-sense RNA
segments. The specific structure allows genetic
reassortment when multiple viruses co-infect the
same cell. Based on the different surface glyco-
proteins, influenza A viruses are further classified
into 16 types of hemagglutinin (HA) and nine
types of neuraminidase (NA).1 Avian hosts are
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the major reservoirs for all subtypes. So far, only
three types of HA (H1, H2, H3) and two types
of NA (N1, N2) have been widely prevalent in
humans.
An influenza pandemic can develop with the
emergence of a new virus with high transmission
capability, and that harbors a novel HA that has
not circulated for decades. In each past pandemic,
a limited wave has appeared first, followed by
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encephalitis.8,9 Myositis often occurs 3 days (range,
0–18 days) after influenza onset.10,11 In young
infants, influenza can mimic sepsis.12 Myocarditis
is a rare complication. Epidemiologically, excess
death occurs mainly in infants and the elderly
(> 65 years old) due to decreased immunity against
influenza virus infection in annual influenza
epidemics. The mortality curve typically presents
with a U-shape when age-specific excess mortality
due to pneumonia and influenza is plotted.
1957 H2N2 and 1968 H3N2 Pandemics—
Epidemiology and Clinical
Manifestations
The 1957 and 1968 pandemics were caused by
Asian influenza A (H2N2) strain and Hong Kong
influenza A (H3N2) strain, respectively. Both vi-
rus strains first emerged in China. Virologic study
showed that these two strains were derived from
genetic reassortment between human and Eurasian
avian lineage influenza virus strains.13 The HA gene
segment of the human strains was replaced by those
of the avian strains; human influenza virus-derived
internal proteins except for PB1 were preserved.14
In these two pandemics, common manifestations
were similar to those of a typical influenza syn-
drome. Patients with underlying cardiovascular
diseases tended to have severe complications. The
U-shaped mortality curve in the 1957 and 1968
pandemics had two ends, peaking in infants and
the elderly.15
The most frequent complication leading to
death was pneumonia. Due to advances in anti-
bacterial therapy, fatal cases caused by primary in-
fluenza viral pneumonia without secondary bac-
terial infections increased. Louria et al reported 33
patients with Asian influenza A infection during
the pandemic of 1957–1958,16 of whom 72.7%
(24/33) had chronic diseases or were pregnant
and 21.2% (7/33) had leukopenia. Liver function
tests were normal except for elevated aspartate
transaminase levels in 76.2%. No renal damage or
hematologic abnormalities, including thrombocy-
topenia or abnormal blood clotting functions, were
global spread in the following year. It has been
generally believed that avian influenza virus
cannot infect humans because of its inability to
bind to the 2-6-linked sialic acid receptors pre-
sent in the human respiratory tract. In 1997, how-
ever, 18 human cases of avian influenza A H5N1
infection occurred in Hong Kong.2 Furthermore,
extensive outbreaks of avian H5N1 infections
with sporadic human spread have been ongoing
in Vietnam, Thailand, Indonesia and Cambodia
since 2003, although human-to-human trans-
mission remains limited.3,4 This particular H5N1
virus has shown increased virulence in mammals,
a warning sign that it is continuously evolving to
adapt to humans and mammals.5
The emergence of an influenza virus strain
with high transmissibility among humans, either
through reassortment between avian and human
influenza viruses or virus mutation, is expected
to occur. Given the threat of a global pandemic
caused by avian H5N1 influenza A virus, we ana-
lyze the clinicopathologic manifestations in his-
toric pandemics and compare them with recent
human H5N1 infections in Asia to gain new in-
sights into the pathogenicity of influenza viruses.
Taking lessons from past experience will be useful
in the development of treatment and prevention
strategies in future influenza pandemics.
Typical Influenza Syndrome—
Epidemiology and Common Features
Clinically, influenza is usually a self-limiting dis-
ease characterized by abrupt onset of fever and
chills accompanied by headache, diffuse myalgia,
rhinorrhea, sore throat and cough. Gastrointesti-
nal discomforts such as vomiting, abdominal pain
and diarrhea are not infrequent. The most com-
mon cause of hospitalization is lower respiratory
tract infection ranging from croup, bronchitis,
bronchiolitis to pneumonia.6,7 Meanwhile, mani-
festations involving the central nervous system may
be observed, leading to encephalopathy,
post-influenza encephalitis, transverse myelitis,
Guillain-Barré syndrome and acute necrotizing
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observed. The death rate related to acute illness
was 27.3% (9/33). Some rapidly progressive cases
presenting with dyspnea and cyanosis resembled
those observed in the 1918 pandemic.17 Oseasohn
et al reported the clinicopathologic study of 33 fa-
tal cases caused by Asian influenza, mostly focus-
ing on previously healthy young individuals dying
rapidly during the course of the disease.17 Postmor-
tem examination showed pulmonary congestion,
edema, intra-alveolar hemorrhage, varying degrees
of consolidation and hyaline membrane formation
indistinguishable from the pathologic findings of
the 1918 pandemic. Staphylococcus aureus was the
most common superimposed pathogen; 39.4%
(13/33) of patients had evidence of myocarditis,
and 12.1% (4/33) was diagnosed with encephalo-
pathy.17 There were no specific findings involving
the gastrointestinal organs except in two patients:
one had inflammatory changes in the esophagus
and pancreas while the other had hemorrhagic con-
gested changes in the colon.
1918 Pandemic—Distinct Epidemiology
and Clinical Features
The geographic origin of the 1918 pandemic re-
mains controversial, with two suspected sites of
origin. One was from China, which then spread to
the USA and Europe through laborer migration.
Another was from the USA as the first outbreaks
occurred simultaneously in Detroit, South Caroli-
na and San Quentin Prison in March 1918, then
spreading unevenly throughout the United States
and Europe.18 In the 1918 pandemic, 50% of the
world’s population was infected and 25% devel-
oped significant clinical infections.
The 1918 influenza pandemic occurred 28 years
after the previous 1890 pandemic. The most sig-
nificant difference in the epidemiology of the 1918
pandemic was the unusual W-shaped mortality
pattern, with a peak of excess death among young
adults aged between 20 and 40 years.15 Excess mor-
tality was not found among the elderly, possibly
due to previous exposure to an influenza virus
antigenically similar to the 1918 strain.15 The 1918
virus strain was thought to be more virulent, caus-
ing 40–50 million deaths worldwide. In fact,
recombinant viruses containing the HA gene seg-
ment of the 1918 pandemic virus were shown to
exhibit high pathogenicity in mice that are not
usually susceptible to other human influenza
viruses.19 The lungs of mice infected with the 1918
virus showed extensive inflammation and con-
tained high levels of macrophage-derived chem-
okines and cytokines.19,20 Gene sequencing of
the 1918 influenza virus suggested that this strain
was an avian influenza virus that adapted to
humans.21
Clinical manifestations were characterized by
acute onset, chills, quick and high rise in body
temperature, frequent epistaxis (hemorrhagic vag-
inal discharge in females), distressing aches and
pains, and increasing prostration.22 Pneumonia was
the most common complication, regardless of
whether it was combined with secondary bacterial
infection or not.22,23 In severe cases, shortness of
breath accompanied by mahogany spots around
the mouth and violaceous heliotrope cyanosis
developed. Within 24–48 hours, patients suffocat-
ed to death and had blood-stained fluid in the
mouth. These signs were compatible with acute
pulmonary edema, proved at autopsy.23 Brem et al
reported that many cases demonstrated hemorrhag-
ic phenomenon and leukopenia in the initial
stages, which indicated blood dyscrasia.24 Of the
fatal cases, 51.8% had initial leukocyte counts
) 5000/mm3, while 21.7% of the non-fatal cases
did.24 Leukopenia was highly associated with fatal
outcome in the 1918 pandemic (chi-square test,
p < 0.001). Due to limited laboratory examinations
at that time, it was not certain if bleeding tenden-
cy was related to thrombocytopenia or abnormal
clotting times. The 1918 virus strain had suppres-
sive effects on bone marrow, and led to hosts be-
coming more vulnerable to certain bacteria such
as Streptococcus pneumoniae, S. hemolyticus and
S. viridans.24 Postmortem lung examinations re-
vealed extensive lung damage throughout the
respiratory tree. Another striking finding was the
enormous number of large mononuclear cells in
the lungs in the earlier stages of the disease.23
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The constellation of leukopenia, hemorrhagic
diathesis and pulmonary edema in healthy young
adults during the 1918 pandemic were unique fea-
tures that contrasted with those observed in the
1957 and 1968 pandemics and during the inter-
pandemic periods. There were specific extrapul-
monary findings reported as well in the 1918
pandemic. Lecount described distinctive patho-
logic features among 200 influenza A cases.25
Splenomegaly, superficial fatty change of the liver,
swelling of the kidneys and brain tissue were fre-
quently found. Sometimes, generalized jaundice
and hyperplasia of lymphoid tissue were observed.
Walker reported 100 autopsy cases at Camp
Sherman.23 The most common findings other than
those in the respiratory system were pericarditis
(65%), acute liver congestion (67%), acute kidney
congestion (74%), acute spleen congestion (56%)
and jaundice (25%); 48% of cases had acute myo-
carditis and 28% had acute hepatitis with grossly
yellowish livers. Marked fatty degeneration of hepa-
tocytes was seen microscopically.
To sum up, extensive organ involvement was
an outstanding feature in the 1918 pandemic. Up
till now, there has been no evidence of direct virus
invasion of multiple organs.18 As a result, multiple
organ dysfunction might be the result of dysregu-
lation of systemic inflammatory responses. These
findings support the concept that some severe
cases were associated with overactivation of inflam-
matory cytokines, leading to pulmonary edema,
infection-associated hemophagocytic syndrome
and multiple organ failure. Hemophagocytic syn-
drome, first described in 1979, is characterized by
high fever, pancytopenia, hepatosplenomegaly, liv-
er dysfunction, high ferritin and triglyceride levels,
which could account for the leukopenia, bleeding
tendency, splenomegaly, jaundice, hepatic fatty
change and multiple organ failure seen in severe
cases during the 1918 pandemic.26,27 Increased pro-
liferation and overactivation of macrophages
throughout the reticuloendothelial system result-
ed in abnormal phagocytic activity and massive
secretion of cytokines. Rapid viral replication in
the respiratory system led to sustained immune
system activation. The excess inflammatory re-
sponse was the pathogenic pathway to the deadly
complications.
H5N1 Infection in Humans
Avian influenza virus H5N1 could cross the spe-
cies barrier and infect humans as evidenced by the
1997 outbreak in Hong Kong. Analysis of human
H5N1 infections in Hong Kong, Vietnam, Thailand
and Cambodia revealed that fever and cough were
the most common initial symptoms.2–4,28,29 Almost
all patients had clinically apparent pneumonia.
Gastrointestinal symptoms including vomiting,
diarrhea, abdominal pain, pleuritic pain, and
bleeding from the nose and gums have also been
observed early in the course of illness in some cases.
One report described two patients who presented
with an encephalopathic illness and diarrhea with-
out apparent respiratory symptoms. The fatality
rate among hospitalized patients has been high
(33–100%, varying by country), although the over-
all rate is probably much lower.29 Fifty to 80% of
cases had lymphopenia and 33–80% had throm-
bocytopenia. Abnormal liver function was detect-
ed in 61–83% of cases. Acute respiratory distress
syndrome (ARDS) complicated 76.5% (13/17) of
cases in Thailand, and 44.4% (8/18) of cases in
Hong Kong. Multiple organ failure with signs of
renal dysfunction and sometimes cardiac compro-
mise has been common. Most patients did not have
preexisting disease, which was quite different from
what happened during interpandemic periods
when patients with underlying cardiovascular, pul-
monary and renal diseases were more susceptible
to severe influenza infection. Leukopenia, throm-
bocytopenia, ARDS and, particularly, lymphope-
nia were associated with poor outcome.4,29 In se-
vere human H5N1 infections in Hong Kong, re-
active hemophagocytic syndrome was a remarka-
ble pathologic feature in three fatal cases,30,31 as
were increased blood levels of interferon-a, tumor
necrosis factor-_, interleukin-6, soluble inter-
leukin-2 receptor, interferon-induced protein-10
and monokines induced by interferon-a.30,31 Hence,
apparent dysregulation of cytokine responses
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contribute to the pathogenesis of human H5N1
infections.
Immunomodulatory agents are thought to be
beneficial in treating fulminant cases. However,
data concerning treatment efficacy from Vietnam
and Thailand in early 2004 showed that no signi-
ficantly different mortality rates were noted be-
tween patients who had or had not received ster-
oid therapy (50% vs 75%, p = 0.334). In a ran-
domized trial in Vietnam, all four patients given
dexamethasone died.29 It is still premature to con-
clude on the usefulness of steroid treatment in
H5N1 infections because there were many varia-
tions in dose, timing and duration of treatment.
NA inhibitors such as oseltamivir and zanami-
vir are effective against influenza A H5N1 virus,
including the avian flu viruses that caused out-
breaks between 1997 and 1999 and the currently
circulating ones. They inhibit viral replication in
cell cultures, reduce NA activity and protect infect-
ed mice from death.32–35 The use of oseltamivir in
Vietnam and Thailand has been sporadic and failed
to impact significantly on patient survival (67%
and 56%, p = 1.000). However, most of the treat-
ments did not start until 2 days after disease onset.
Experience of zanamivir is lacking. How effective
NA inhibitors are against human H5N1 infection
is not firmly established. Nevertheless, since NA
inhibitors are currently the only options for treat-
ment or prophylaxis in H5N1 human infections,
they form an important part of a strategy for deal-
ing with the possibly upcoming pandemic. In the
1968 and 1977 pandemics, adamantanes were
found to have a protective efficacy of around 70%,
only slightly lower than the efficacy reported
during the interpandemic period. The protective
efficacy of NA inhibitors during a pandemic would
be expected to be at least as high as that of the
adamantanes.32 In view of the recent isolation of
an oseltamivir-resistant H5N1 virus from a Viet-
namese patient, zanamivir should be included as
part of pandemic preparedness in addition to
oseltamivir.
In the influenza A pandemics of 1957 and 1968,
the clinical illnesses were more confined to the
respiratory system, while in the 1918 pandemic and
human H5N1 infections since 1997, multisystem
dysfunction and immune dysregulation developed
in infected individuals. This is an indication that
highly pathogenic influenza A viruses, through
direct adaptation to humans, would stimulate more
severe and inappropriate immune responses than
a reassortant virus.
There have been 12 definite or probable pan-
demics in the past 400 years,36 of which 11 origi-
nated in China, Russia and Asia. No apparent
seasonality was observed, but they occurred more
frequently in spring and summer than in autumn
and winter. Higher temperatures and humidity
would seem to favor the spread of a pandemic.
Conclusion
It has been almost 40 years since the last pandem-
ic in 1968. All the conditions favoring an influen-
za pandemic are looming, including successful
evolvement of a candidate strain (H5N1 influenza
A virus), extensive seeding in Asia, and long-
enough interpandemic time. If our current control
measures implemented in Asia turn out to be in-
adequate, a pandemic in 2006 or 2007 is highly
likely. Appropriate use of NA inhibitors and
judicious modulation of inflammatory cascades
caused by avian influenza A virus may be crucial
to clinical management of human H5N1 in-
fections. Since the risk of influenza A epidemics
and pandemics will remain for the foreseeable
future, newer and improved influenza vaccines
should be developed. More studies on the epi-
demiology, evolution and pathogenesis of avian
influenza A virus infection are warranted.
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